Clinical Trial: Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07621380) titled 'Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction' on May 27.

Brief Summary: This prospective, randomized, open-label, blinded endpoint (PROBE) trial evaluates the efficacy of early ertugliflozin initiation (10 mg daily) compared to standard care alone on cardiac function in 476 adult patients with type 2 diabetes mellitus (T2DM) following a first acute myocardial infarction (AMI). The primary objective is to assess the change in NT-proBNP levels from baseline to 26 weeks, while secondary endpoints explore echocardiographic parameters (such as LVEF and LAVi) and metabolic indices including bloo...